180 related articles for article (PubMed ID: 35081296)
21. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination.
Abbasi J
JAMA; 2021 Sep; 326(10):901. PubMed ID: 34519816
[No Abstract] [Full Text] [Related]
23. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
24. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
[No Abstract] [Full Text] [Related]
25. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
26. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
[No Abstract] [Full Text] [Related]
27. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
[No Abstract] [Full Text] [Related]
28. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
29. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
30. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
[TBL] [Abstract][Full Text] [Related]
31. Audio Interview: Monoclonal Antibodies and Vaccine Boosts.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Jul; 385(3):e18. PubMed ID: 34260844
[No Abstract] [Full Text] [Related]
32. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
[TBL] [Abstract][Full Text] [Related]
33. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
[TBL] [Abstract][Full Text] [Related]
34. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
35. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
36. Audio Interview: How Well Are Covid-19 Vaccines Working?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Jul; 385(2):e15. PubMed ID: 34233102
[No Abstract] [Full Text] [Related]
37. Durability of XBB.1.5 Vaccines against Omicron Subvariants.
Lin DY; Du Y; Xu Y; Paritala S; Donahue M; Maloney P
N Engl J Med; 2024 Jun; 390(22):2124-2127. PubMed ID: 38810167
[No Abstract] [Full Text] [Related]
38. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
Yin Q; Zhang Y; Lian L; Qu Y; Wu W; Chen Z; Pei R; Chen T; Sun L; Li C; Li A; Li J; Li D; Wang S; Guan W; Liang M
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452373
[TBL] [Abstract][Full Text] [Related]
39. Neutralization antibody titer and change in 50% protection after the third dose of the COVID-19 vaccine.
Mungmunpuntipantip R; Wiwanitkit V
Indian J Pharmacol; 2024 Mar; 56(2):80-83. PubMed ID: 38687310
[TBL] [Abstract][Full Text] [Related]
40. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]